BBA
VRDN icon

Baker Bros. Advisors’s Viridian Therapeutics VRDN Stock Holding History

Baker Bros. Advisors’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$43.8M Buy
2,383,025
+411,347
+21% +$6.63M 0.22% 41
2026
Q1 		$38.6M Hold
1,971,678
– – 0.22% 40
2025
Q4 		$61.4M Buy
1,971,678
+227,272
+13% +$6.23M 0.36% 36
2025
Q3 		$37.6M Hold
1,744,406
– – 0.27% 34
2025
Q2 		$24.4M Buy
+1,744,406
New +$23.7M 0.24% 34

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Baker Bros. Advisors's VRDN Position: Q2 2026 in Review

Baker Bros. Advisors increased its Viridian Therapeutics (VRDN) stake by 21% in Q2 2026, buying an estimated $6.63M and bringing the position to 2,383,025 shares worth $43.8M. The position accounts for 0.22% of the portfolio, ranked #41.

Baker Bros. Advisors first reported a position in VRDN in Q2 2025 and has held it in 5 quarters since. The position peaked at $61.4M in Q4 2025. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Baker Bros. Advisors held 2,383,025 shares of Viridian Therapeutics worth $43.8M as of Q2 2026.
  • Baker Bros. Advisors bought 411,347 Viridian Therapeutics shares in Q2 2026, an estimated $6.63M.
  • Viridian Therapeutics made up 0.22% of Baker Bros. Advisors's portfolio in Q2 2026, its #41 holding.
  • Baker Bros. Advisors first reported a position in Viridian Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Baker Bros. Advisors's Viridian Therapeutics position peaked at $61.4M in Q4 2025.
  • 214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Baker Bros. Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.